Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

NVO - Novo Nordisk A/S Последние новости | Finranks

Home

/

NVO

N

Novo Nordisk A/S (NVO)

NYQ – Цена в реальном времени. Валюта: USD

46.24

-0.93 (-1.96%)

Рынок открыт: Aug 12, 2026, 1:14 PM EDT

47.27

+0.10 (0.21%)

Предыдущая сессия: Aug 11, 2026, 7:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America

Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America

Novo Nordisk CEO argues weight loss drugs could slash health care costs and boost productivity as GLP-1 adoption remains in its early innings.

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

NVO faces near-term pressure from flat Wegovy sales, pricing challenges and pipeline setbacks, but its broad cardiometabolic pipeline offers long-term potential.

PHARMA BETS: CEO turns to AI for next-generation drugs

PHARMA BETS: CEO turns to AI for next-generation drugs

Novo Nordisk President and CEO Mike Doustdar discusses the company's collaboration with artificial intelligence to accelerate drug discovery and development.

The Market Is (Still) Underestimating Novo Nordisk

The Market Is (Still) Underestimating Novo Nordisk

Novo Nordisk remains a Buy, underpinned by strong long-term fundamentals and a promising lead in obesity care, especially with the Wegovy pill. Despite near-term challenges—declining gross margins, high CapEx, and a failed ziltivekimab trial—Novo Nordisk's operating margins and capital allocation remain robust. Management raised 2026 guidance, now expecting adjusted sales and operating profit to decline up to 6%, a significant improvement from prior outlooks.

Novo Nordisk Stock: Buy or Sell?

Novo Nordisk Stock: Buy or Sell?

Novo Nordisk (NVO -1.17%) is more than just a weight loss company.

Better Buy: Eli Lilly vs. Novo Nordisk

Better Buy: Eli Lilly vs. Novo Nordisk

Eli Lilly has a stronger GLP-1 portfolio and pipeline than Novo Nordisk. Eli Lilly also has a better lineup outside the diabetes and weight-loss areas.

Novo Nordisk A/S Q2 Earnings Call Highlights

Novo Nordisk A/S Q2 Earnings Call Highlights

Novo Nordisk A/S NYSE: NVO reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins.

Видео

PHARMA BETS: CEO turns to AI for next-generation drugs

Novo Nordisk CEO addresses investors' high Wegovy pill expectations